stockrow
Friday 6 November 2026
Export XNCR’s income statement to Excel — free account
Xencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.
- Revenue
- +17.5%
- EPS
- +29.3%
- Free cash flow
- −52.9%
Quarter to June 2026, against a year earlier
36.21
2.16
+6.34%
Follow XNCR
Alert me
Xencor, Inc. (XNCR) Net income
Xencor, Inc.'s net income for fiscal 2025 was −$92.1M, compared with −$236.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$163.3M. Over the past ten years it has ranged from −$236.5M (fiscal 2024) to $82.6M (fiscal 2021); the current reading is higher than 27% of that period. Xencor, Inc. ranks 493rd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$92.1M | — |
| FY2024 | −$236.5M | — |
| FY2023 | −$133.3M | — |
| FY2022 | −$55.2M | — |
| FY2021 | $82.6M | — |
| FY2020 | −$69.3M | — |
| FY2019 | $26.9M | — |
| FY2018 | −$70.4M | — |
| FY2017 | −$38.5M | — |
| FY2016 | $45.1M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$21.7M | — |
| Mar 2026 | −$128.9M | — |
| Dec 2025 | −$6.7M | — |
| Sep 2025 | −$6.0M | — |
| 42 more quarters | Free account |
Against its own ten years
Low −$236.5M
High $82.6M
Ten-year median
−$55.2M
Current reading's percentile
27
Net income against peers
| Company | Net income |
|---|---|
| ADMA ADMA Biologics Inc compare | $182.4M |
| MBX MBX Biosciences, Inc. compare | −$104.3M |
| BEAM Beam Therapeutics Inc. compare | −$108.4M |
| XNCR Xencor, Inc. | −$163.3M |
| PHVS Pharvaris N.V. compare | −$193.1M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$198.4M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$204.9M |
| RCUS Arcus Biosciences, Inc. compare | −$453.0M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$475.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on XNCR
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement